SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+32.69%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$324M
(+21%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-23.19%
Top 10 Holdings %
Top 10 Hldgs %
40.14%
Holding
88
New
16
Increased
27
Reduced
15
Closed
20
Top Buys
| 1 |
Nuvalent
NUVL
|
$14.2M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$11.5M |
| 3 |
Medtronic
MDT
|
$11.1M |
| 4 |
Sanofi
SNY
|
$10.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$9.8M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$85.4M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$20.7M |
| 3 |
Soleno Therapeutics
SLNO
|
$11.9M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$9.22M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$8.76M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biogen
BIIB
$19.4B
| $5.18M | 1.54% |
20,000
-8,069
| -29% | -$2.09M |
|
|
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
| $5.17M | 1.54% |
218,975
-371,025
| -63% | -$8.76M |
|
28
Caribou Biosciences
CRBU
$174M
| $5.16M | 1.54% |
900,818
+8,032
| +0.9% | +$46K |
|
29
Scholar Rock
SRRK
$3.14B
| $5.08M | 1.51% |
270,000
+260,289
| +2,680% | +$4.89M |
|
30
Penumbra
PEN
$10.6B
| $5.03M | 1.5% |
+20,000
| New | +$5.03M |
|
31
Insmed
INSM
$28.8B
| $4.82M | 1.43% |
155,504
+5,117
| +3% | +$159K |
|
32
Sarepta Therapeutics
SRPT
$1.78B
| $4.52M | 1.35% |
46,884
+37,687
| +410% | +$3.63M |
|
33
DexCom
DXCM
$29.5B
| $3.85M | 1.15% |
+31,000
| New | +$3.85M |
|
34
Solid Biosciences
SLDB
$427M
| $3.65M | 1.09% |
+594,855
| New | +$3.65M |
|
35
United Therapeutics
UTHR
$13.8B
| $3.6M | 1.07% |
16,360
-15,064
| -48% | -$3.31M |
|
36
Terns Pharmaceuticals
TERN
$609M
| $3.36M | 1% |
516,999
+16,999
| +3% | +$110K |
|
37
Cerus
CERS
$251M
| $3.24M | 0.96% |
1,499,851
+295,961
| +25% | +$639K |
|
38
Kodiak Sciences
KOD
$478M
| $3.04M | 0.9% |
1,000,000
-114,461
| -10% | -$348K |
|
39
Biohaven
BHVN
$1.63B
| $3.03M | 0.9% |
70,695
+60,695
| +607% | +$2.6M |
|
40
MoonLake Immunotherapeutics
MLTX
$3.54B
| $3.02M | 0.9% |
+50,000
| New | +$3.02M |
|
|
41
Soleno Therapeutics
SLNO
$3.6B
| $2.97M | 0.88% |
73,665
-296,335
| -80% | -$11.9M |
|
42
Evogene
EVGN
$10.9M
| $2.6M | 0.78% |
3,100,000
| – | – |
|
43
Mirum Pharmaceuticals
MIRM
$3.71B
| $2.39M | 0.71% |
80,811
-29,303
| -27% | -$865K |
|
44
Zura Bio
ZURA
$133M
| $2.16M | 0.64% |
462,997
+58,957
| +15% | +$275K |
|
45
Annexon
ANNX
$226M
| $1.9M | 0.56% |
417,429
+17,713
| +4% | +$80.4K |
|
46
Compugen
CGEN
$132M
| $1.86M | 0.55% |
940,000
+589,812
| +168% | +$1.17M |
|
47
argenx
ARGX
$43.6B
| $1.84M | 0.55% |
+4,826
| New | +$1.84M |
|
48
89bio
ETNB
$1.34B
| $1.77M | 0.53% |
158,719
+98,472
| +163% | +$1.1M |
|
49
PMV Pharmaceuticals
PMVP
$74.2M
| $1.71M | 0.51% |
+550,000
| New | +$1.71M |
|
50
Altimmune
ALT
$338M
| $1.69M | 0.5% |
+150,000
| New | +$1.69M |
|